Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia

April 1, 2019 Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia

Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …
News

Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’

April 1, 2019 Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde

Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …
News

Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics

April 1, 2019 Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma

Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …
News

Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

April 1, 2019 Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
News

Lyrica to be made class C drug in Northern Ireland

April 1, 2019 Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin

Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …
News

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019 Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
News

Top Ten most popular articles on Pharmafile.com this week!

March 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

A Japanese journalist was ordered to pay Â¥3.3 million to an anti-vaccine researcher, this week, after a court found her …
News

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019 Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
News

Working Life: Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering

March 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Working Life, feature

Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.How did …
Feature

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019 Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
News

Gilead accused of ripping off US taxpayers

March 28, 2019 Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
News

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019 Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
News

Novartis’ new MS drug to cost $88,000 a year

March 27, 2019 Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
News

Conducting internal investigations within a pharmaceutical business

March 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Reed Smith, feature, internal investigations, pharma

Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a …
Feature

Sanofi and Lexicon’s Zynquista denied type 1 diabetes approval by FDA complete response letter

March 25, 2019 Sales and Marketing Zynquista. FDA, diabetes, pharma

Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …
News
The Gateway to Local Adoption Series

Latest content

From lab breakthrough to NHS treatment: Getting innovative therapies to patients

September 5, 2026

Five Facts about NHS and primary care

September 5, 2026

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.

September 5, 2026

AI in pharma: From lab development to patient impact

September 5, 2026

Back to basics: X-ray inspection in pharmaceutical and medical device production

September 5, 2026